M3 Biotechnology CEO Leen Kawas told a television interviewer Thursday that she is convinced the growing focus on regenerative medicine will help the impetus to bring to market her company’s drug that would reverse neurodegenerative diseases.
Kawas was a guest on Q13 Fox News 4pm newscast, where she was interviewed by Marni Hughes, who inquired about M3, its initial focus on reversing Parkinson ’s disease and Alzheimer’s and whether a cure for Parkinson’s lies ahead.
“The opportunity for a cure is certainly closer than it has ever been and our drug now moving from animal testing toward clinical trials gives us cause for great optimism about a cure,” Kawas said.
“Regenerative medicine is a targeted new branch of medical science and the focus on cellular regeneration makes the pill we are developing that would reverse the cellular death that characterizes these terrible diseases a timely component of regenerative medicine,” Kawas said.
And Hughes asked about the challenges Kawas personally faced as a young Jordanian coming to Washington State University to get her PhD. Kawas was involved in the discovery of MM-201 then eventually grew into the role of heading the start-up company that is involved in the development and commercialization of the drug.
She talked about her good fortune in encountering, when she arrived at WSU, a supportive environment, including Joe Harding, PhD, in whose lab the drug with its crucial growth-factor activating characteristic was developed over more than a decade.
In response to Hughes’ question about the importance of funding and grants from organization like the Alzheimer’s Drug Discovery Foundation Kawas called such funding “not just important but vital to the eventual success of companies like ours that are start-ups representing high-risk investments at this early stage.”
In preparing for the interview Kawas talked about the importance during her growing-up years of parents who made sure that she understands that there is not limits. “The sky is not the limit, is a key thing I learned from them.”
FOR FURTHER INFORMATION, PHOTOS CONTACT:
Mike Flynn (email@example.com, cell 206/240-5368)